Showing results (221-230 of 317) with videos related to

Sort By:
Pageof 32
Haematologica|September 9, 2017
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531Andrew P Voigt, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Journal of Hematology & Oncology|October 22, 2015
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology GroupGeorge S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Bioconjugate Chemistry|March 31, 2026
Systematic Evaluation of Maleimide Spacer Impact on Drug-Linker Deconjugation in Antibody-Drug Conjugates <i>Ex Vivo</i> and <i>In Vivo</i>Andrea Hernández Rojas, Jodi Wong, Diego A Alonzo, et al.
JCO Global Oncology|December 16, 2022
Safety and Acceptability of Three Ablation Treatments for High-Grade Cervical Precancer: Early Data From a Randomized Noninferiority Clinical TrialMontserrat Soler, Karla Alfaro, Rachel J Masch, et al.
British Journal of Haematology|May 21, 2013
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology GroupNorman J Lacayo, Todd A Alonzo, Urte Gayko, et al.
Blood|April 16, 2017
Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group reportMarijana Vujkovic, Edward F Attiyeh, Rhonda E Ries, et al.
Leukemia|June 10, 2022
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trialsMohammed O Gbadamosi, Vivek M Shastri, Abdelrahman H Elsayed, et al.
Blood|August 19, 2011
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971Alan S Gamis, Todd A Alonzo, Robert B Gerbing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2024
Influence of Nucleophosmin (<i>NPM1</i>) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup CollaborationClaudia Tregnago, Maddalena Benetton, Rhonda E Ries, et al.
Blood Advances|May 12, 2026
Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexityJohn N Colgan, Jack H Peplinski, Yi-Cheng Wang, et al.
Pageof 32